Reddit's users wobble while pharma ads grow 50%: what the October 29 print decides

Wedbush sees daily-user pressure into the October 29 report; Reddit's pharma desk sees a category compounding above 50% because AI models scrape the site for health answers. One stock, two readings of the same quarter.

Vincent JiangVincent Jiang · 3 min read
Share
Reddit CEO Steve Huffman speaking on stage at the Goldman Sachs Private Innovative Company Conference in 2018
1 / 6Slide 1 of 6
Reddit CEO Steve Huffman at the Goldman Sachs Private Innovative Company Conference, November 2018. Reddit reports third-quarter results on October 29.

Reddit−3.60% — Reddit, down 3.60 percent today reports Q3 earnings on October 29, and the two loudest signals before the print point in opposite directions 21. Wedbush flagged near-term pressure on daily active users heading into the quarter 2, while Reddit's own pharma partnerships head, Jess Calef, said pharmaceutical revenue and spend on the platform grew more than 50% year over year as of Q2 1. The stock fell 1.56% on October 23 as investors weighed which number will govern 2.

The bear camp: the audience stopped growing

The user case is simple. Reddit reported 130.3 million daily active uniques in Q2, up 18% year over year, but search referral traffic turned irregular and declining toward the end of the quarter, and shares are down roughly 36% this year, underperforming Meta−1.36% — Meta, down 1.36 percent today, Pinterest−2.75% — Pinterest, down 2.75 percent today and Snap 3. Wedbush expects that pressure to show up in the Q3 user count 2. If the audience stalls, the bear argument runs, the ad business cannot keep compounding forever.

The bull camp: ads are growing faster than users

The revenue case rests on pricing and category mix, not headcount. Q2 international revenue rose 84% year over year and global ARPU climbed 36% to $6.18 3. Management guides Q3 revenue to $860–870 million, about 48% growth at the midpoint 3. Pharma is the fastest-growing slice: Calef put pharma spend and revenue above 50% year-over-year growth as of Q2, with health conversations accruing more than 36 billion views over the past year and 61% of US health-information seekers using Reddit as a "final check" before taking action 1.

Pharma ad spend and revenue are growing faster than Reddit's audience

  • Estimate
020406080100Intl revenue (Q2)84Pharma ad spend50Global ARPU36Daily actives18
Data
Value
Intl revenue (Q2)84
Pharma ad spend (estimate)50
Global ARPU36
Daily actives18
Year-over-year growth rates. Pharma figure is company-stated 'more than 50%' as of Q2 2026, charted at 50% as an estimate; all others reported Q2 2026 figures. Sources: MM+M (pharma), Zacks via MSN (all reported figures).1,3

The reason drugmakers pay is machine-readable. LLMs like Claude, ChatGPT and Gemini scrape Reddit's text to answer health queries, so pharma brands buy placements to sit in what MM+M calls AI's circulatory system 1. Reddit built MLR-compliant ad placements with agencies CMI Media Group and Compas, and Genentech shaped a caregiver campaign by analyzing conversations across more than 700 health-related subreddits 1. Calef's pitch: AI does not replace Reddit, and Redditors who use AI go 46% deeper on the platform than those who do not 1.

The cross-examination

Both camps cite the same Q2 report 1. The bears cite the user line; the bulls cite the revenue line; the pharma claim, above 50% growth, is a company figure delivered at an industry event, not an audited segment disclosure 1.

What resolves it is not argument but arithmetic on October 29: whether daily uniques accelerate or decelerate against the 18% Q2 rate, and whether revenue beats the $886 million consensus 23. High-margin category growth on a flat user base is a real business; it is also a business with a ceiling, and the Q3 print is where investors find out how far off that ceiling is 23.

Get Applications by email, free

How AI is changing the software people and companies use. In our daily email, every weekday.

Loading RDDT…

Reader comments

0 comments

    More in Applications

    All in this topic →

    Applications

    Spotify jumped 11.1% betting agents cannot cancel it; December's bar is 10 million net additions

    Spotify rebuilt itself as an agent Muse, ChatGPT and Claude can talk to, keeping playback and data in-house; LightShed's Rich Greenfield posed the churn case on the same call. The December quarter, the first full one under the price rises behind a 9.3% ARPU gain, settles which camp priced the stock right.

    Applications

    A third of leading US commerce sites block Meta's Muse. Googlebot walks in.

    Jefferies tested Meta's Muse agent across several hundred leading US shopping and travel sites and found about a third block it outright, with new restrictions appearing almost daily. The take-rate revenue meant to justify Meta's record capex must now be negotiated door by door, and merchants dare not close the one door Google uses.

    Applications

    ASUS sells out its $1,299 Xbox handheld in five days as PC shipments slide 21%

    The ROG Xbox Ally X20 and its $2,499 XREAL bundle vanished from Best Buy and ASUS.com within five days of launch. Counterpoint's Q3 count shows why that matters: the PC market fell 21% and ASUS held up better than any top-five rival.

    Applications

    Canva launches its own Craft image model as Ideogram prices editable design files at up to 32 cents

    Ideogram and Canva shipped rival models for the same job on October 22, and every rung of AI-assisted design now carries a public price: a cent for an image, six cents for an edit, up to 32 cents for a file a designer can own. Buyers win on price; the platforms that once rented models now build them.

    Applications

    Netflix names Peter Rice content chief and cuts 1,000 jobs as 2026 ad revenue forecast falls to $2.7 billion

    Bela Bajaria is out, Peter Rice is in, and the only scoreboard investors get is viewing hours that grew 2% in six months. Wall Street is splitting between a patient buy and a waiting sell.

    Applications

    Accenture re-rated from 9.8 to 18.6 times earnings as its Asia-Pacific co-CEO sold $1.4 million

    Accenture's stock re-rated from 9.8 times earnings to 18.6 in four months, while management disclosed falling prices and its Asia-Pacific co-CEO sold $1.4 million outside any trading plan. On December 17, consulting revenue growth says who is right.

    Get the newsletter

    The day's AI and market news, in your inbox every weekday.